SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Kilitch Drugs (India) informs about issuance of duplicate share certificate

28 Feb 2024 Evaluate

Pursuant to Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, Kilitch Drugs (India) has informed that the Company has received intimation from the Registrar and Share Transfer Agents of the Company - Link Intime India for issue of duplicate share certificate as details enclosed. 

The above information is a part of company’s filings submitted to BSE.

Kilitch Drugs(India) Share Price

130.55 0.65 (0.50%)
16-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1693.15
Dr. Reddys Lab 1221.25
Cipla 1230.75
Zydus Lifesciences 939.20
Lupin 2326.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×